# Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Source: https://onco.cc/trials/nct06202001/  
OnCo record `nct06202001` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in colorectal cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.

## Summary

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients is a phase 1/2, interventional study registered as NCT06202001 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 70 participants, started 2022-10-01 and due to reach its primary completion in 2025-09-30. Interventions recorded: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "Colorectal adenocarcinoma confirmed histologically or histopathologically". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06202001
- Phase: 1/2
- Setting: Phase I/II Study of Irinotecan Plus Trifluridine/Tipiracil (TAS-102) in Combination With Bevacizumab as a Second-Line Therapy for Patients With Metastatic Colorectal Cancer (mCRC)
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06202001: https://clinicaltrials.gov/study/NCT06202001

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06202001.json